Key facts
- It has raised $2.8M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Zheshang Venture Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ultra-Theranostics Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Ultra-Theranostics Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ultra-Theranostics Biopharmaceuticals
Manufacturer of integrated therapeutic and diagnostic compounds designed for oncology applications. The company offers advanced chemical synthesis, nanoparticle-based delivery systems, and real-time imaging capabilities that allow tracking of compound distribution within tumor regions, enabling the biopharmaceutical market to improve drug utilization, enhance treatment precision, reduce systemic toxicity, and support the development of next-generation targeted therapies through combined diagnostic and therapeutic functionality.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2023
- Employees
- 11
- Website
- ultra-theranostics.com/
- Ownership
- Privately Held (backing)
Ultra-Theranostics Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ultra-Theranostics Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ultra-Theranostics Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.